Q3 2020 Sales Performance

Progress on portfolio of COVID-19 solutions 3 vaccine approaches in the clinic SANOFI medicago Clover Biopharmaceuticals Sanofi's recombinant protein-based antigen + GSK's AS03 adjuvant FTIH studies initiated September 2020 – Data expected by year end 2020; pivotal study start anticipated by year end - Medicago's recombinant Coronavirus Virus-Like Particles (COVLP) + GSK's AS03 adjuvant FTIH studies initiated July 2020 Data expected to be published shortly; pivotal study start anticipated by year end Clover's COVID-19 S-Trimer vaccine (SCB 2019) + GSK's AS03 adjuvant - FTIH studies initiated June 2020 Data expected to be published shortly; pivotal study start anticipated by year end 2 therapeutics in pivotal studies - gsk Vir7831: neutralizing human monoclonal antibody, specifically engineered for SARS-COV-2 Potential to be best-in-class: designed for maximum bioavailability in the lung; long half-life following single infusion; optimal binding to virus even if it subsequently mutates - COMET-ICE pivotal study ongoing with initial data possible by end 2020 - otilimab: aGM-CSF antibody, targeting a cytokine found in high levels in COVID patients - For treatment of severe pulmonary COVID-19 related disease - OSCAR study ongoing, with data expected 1H 2021 - Also in Phase 3 studies for rheumatoid arthritis 8

View entire presentation